stars 1 stars 2 stars 3

T&R Biofab is a science-driven and product-oriented company which has developed and produced their own 3D Bio-printing System for the creation of biodegradable scaffolds, Bio-ink, 3D Organoid Models, Cytotherapeutic Agents, and Artificial Organs At the beginning, T&R Biofab started its business with the development of 3D Bio-printing equipment. At that time, T&R recognized that there were lots of promises on the bioprinting field that would need a consistent development to make it become a reality, and the use of other cutting-edge technologies such as biomimetic biomaterials and pluripotent stem cells would help to achieve these promises. Currently, after securing key IP, filing over 100 patents, and expanding our area of research, using iPS cells and special biomaterials; T&R has the core technology to develop artificial organs such as skin, heart, and liver, having publications on the most renown scientific journals of the world (Biofabrication, Biomaterials, Small, Nature Communications, Advanced Materials, etc.) The CEO, Dr. Wonsoo Yun, set T&R’s major goal as to change people’s life through relieving the pain of the ones in need. This dream is being achieved using our proprietary biomedical solutions and innovative thinking. Partnering with key players, T&R is reaching more patients making: patient specific implants for reconstruction of damaged areas of the face, cranio-maxillofacial mesh to repair or smooth defects from surgeries, among other confidential applications (in development under CDA). T&R has an increasing interest in organ reconstruction (liver) and cell therapy applications (CAR T, Cardio), and we hope you will join T&R Biofab on our journey to change the biomedical world. #TnRBiofab #TissueEngineering #Healthcare #Bioprinting #MedicalDevices #CellTherapy

Website http://www.tnrbiofab.com/en/
Ticker KOSDAQ:246710
Revenue $5.9 million
Employees 27 (11 on RocketReach)
Founded 2013
Phone +82 31-431-3344
Industry Biotechnology, Biotechnology Research, Business Services General, 3D Printing, Business Services, Manufacturing, Other Devices and Supplies, 3D Technology, Hardware, Software, Science and Engineering
Competitors Geno, Amyris, Zymergen, Inc., Sustainable Bioproducts, LanzaTech, Viridos, Arzeda, Propel Fuels, Solugen, Amalfi Bio, Inc +45 more (view full list)
SIC SIC Code 873 Companies, SIC Code 87 Companies
NAICS NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies

T&RBiofab Questions

The T&RBiofab annual revenue was $5.9 million in 2026.

Won-Soo Yun is the CEO of T&RBiofab.

11 people are employed at T&RBiofab.

T&RBiofab is based in Seoul, Seoul.

The NAICS codes for T&RBiofab are [54, 541, 541713, 5417, 54171].

The SIC codes for T&RBiofab are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users